Journal
CURRENT CARDIOLOGY REPORTS
Volume 16, Issue 7, Pages -Publisher
SPRINGER
DOI: 10.1007/s11886-014-0501-8
Keywords
Heart failure; Diastolic dysfunction; Heart failure with preserved ejection fraction; Diastolic heart failure; Hemodynamics; Ventricular function
Categories
Funding
- Amgen
- GlaxoSmithKline
- Atcor Medical
- Medscape
- Merck
- Gilead
Ask authors/readers for more resources
Heart failure (HF) is the leading cause of hospitalization among older adults and the prevalence is growing with the aging populations in western countries. Approximately one-half of patients with HF have preserved ejection fraction (HFpEF). In contrast to HF with reduced EF (HFrEF), there is no proven effective treatment for HFpEF. The pathophysiology of HFpEF is complex, and the dominant mechanisms leading to symptoms of HF often vary between afflicted patients, confounding efforts to apply one-size fits all types of therapeutic approaches. Current treatment strategies focus on control of volume status and comorbidities, but future research aimed at individualized therapies holds promise to improve outcomes in this increasingly prevalent form of cardiac failure.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available